{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:21:44Z","timestamp":1769127704921,"version":"3.49.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1097\/md.0000000000006239","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T11:47:41Z","timestamp":1488368861000},"page":"e6239","source":"Crossref","is-referenced-by-count":5,"title":["Effect of contraindicated drugs for heart failure on hospitalization among seniors with heart failure"],"prefix":"10.1097","volume":"96","author":[{"given":"Catherine","family":"Girouard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyne","family":"Moisan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-41-20210309","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/CIR.0b013e3182456d46","article-title":"Executive summary: heart disease and stroke statistics\u20142012 update: a report from the American Heart Association","volume":"125","author":"Roger","year":"2012","journal-title":"Circulation"},{"key":"R2-41-20210309","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/CIRCULATIONAHA.109.192064","article-title":"2009 focused update: ACCF\/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation","volume":"119","author":"Jessup","year":"2009","journal-title":"Circulation"},{"key":"R3-41-20210309","first-page":"e240","article-title":"2013\u200aACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"R4-41-20210309","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cjca.2012.10.007","article-title":"The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure","volume":"29","author":"McKelvie","year":"2013","journal-title":"Can J Cardiol"},{"key":"R5-41-20210309","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jgs.12062","article-title":"Patterns of comorbidity in older adults with heart failure: the Cardiovascular Research Network PRESERVE study","volume":"61","author":"Saczynski","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"R6-41-20210309","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.amjmed.2010.08.017","article-title":"Trends in comorbidity, disability, and polypharmacy in heart failure","volume":"124","author":"Wong","year":"2011","journal-title":"Am J Med"},{"key":"R7-41-20210309","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ahj.2013.07.008","article-title":"Measuring frailty in heart failure: a community perspective","volume":"166","author":"McNallan","year":"2013","journal-title":"Am Heart J"},{"key":"R8-41-20210309","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/gerona\/gls001","article-title":"Prevalence of potentially preventable unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events among older veterans","volume":"67","author":"Marcum","year":"2012","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R9-41-20210309","first-page":"385","article-title":". The Multicenter Diltiazem Postinfarction Trial Research Group.","volume":"319","year":"1988","journal-title":"N Engl J Med"},{"key":"R10-41-20210309","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/01.CIR.83.1.52","article-title":"Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group","volume":"83","author":"Goldstein","year":"1991","journal-title":"Circulation"},{"key":"R11-41-20210309","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1161\/01.CIR.82.6.1954","article-title":"A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure","volume":"82","author":"Elkayam","year":"1990","journal-title":"Circulation"},{"key":"R12-41-20210309","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/01.CIR.0000154542.13412.B1","article-title":"Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study","volume":"111","author":"Masoudi","year":"2005","journal-title":"Circulation"},{"key":"R13-41-20210309","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archinternmed.2008.525","article-title":"Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure","volume":"169","author":"Gislason","year":"2009","journal-title":"Arch Intern Med"},{"key":"R14-41-20210309","doi-asserted-by":"crossref","first-page":"160","DOI":"10.24095\/hpcdp.33.3.06","article-title":"Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records","volume":"33","author":"Schultz","year":"2013","journal-title":"Chronic Dis Inj Can"},{"key":"R16-41-20210309","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/archinte.164.7.709","article-title":"Keeping your patient with heart failure safe: a review of potentially dangerous medications","volume":"164","author":"Amabile","year":"2004","journal-title":"Arch Intern Med"},{"key":"R17-41-20210309","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1100\/tsw.2001.58","article-title":"Accumulation of deficits as a proxy measure of aging","volume":"1","author":"Mitnitski","year":"2001","journal-title":"ScientificWorldJournal"},{"key":"R18-41-20210309","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/gerona\/59.12.1310","article-title":"Prevalence, attributes, and outcomes of fitness and frailty in community-dwelling older adults: report from the Canadian study of health and aging","volume":"59","author":"Rockwood","year":"2004","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R19-41-20210309","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2318-8-24","article-title":"A standard procedure for creating a frailty index","volume":"8","author":"Searle","year":"2008","journal-title":"BMC Geriatr"},{"key":"R20-41-20210309","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.105.568451","article-title":"Cyclooxygenase inhibition and cardiovascular risk","volume":"112","author":"Antman","year":"2005","journal-title":"Circulation"},{"key":"R22-41-20210309","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"R23-41-20210309","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","article-title":"Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2","volume":"296","author":"McGettigan","year":"2006","journal-title":"JAMA"},{"key":"R24-41-20210309","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2106\/00004623-201310160-00010","article-title":"The American Academy of Orthopaedic Surgeons evidence-based guideline on: treatment of osteoarthritis of the knee, 2nd edition","volume":"95","author":"Jevsevar","year":"2013","journal-title":"J Bone Joint Surg Am"},{"key":"R25-41-20210309","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1532-5415.2009.02376.x","article-title":"Pharmacological management of persistent pain in older persons.","volume":"57","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"R26-41-20210309","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group","volume":"23","author":"Aronoff","year":"2000","journal-title":"Diabetes Care"},{"key":"R27-41-20210309","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1210\/jcem.86.1.7157","article-title":"Rosiglitazone monotherapy is effective in patients with type 2 diabetes","volume":"86","author":"Lebovitz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-41-20210309","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"R29-41-20210309","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","article-title":"Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis","volume":"298","author":"Singh","year":"2007","journal-title":"JAMA"},{"key":"R30-41-20210309","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00129784-200303010-00004","article-title":"Defining the role of calcium channel antagonists in heart failure due to systolic dysfunction","volume":"3","author":"Mahe","year":"2003","journal-title":"Am J Cardiovasc Drugs"},{"key":"R31-41-20210309","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/CIRCULATIONAHA.109.192064","article-title":"2009 Focused Update: ACCF\/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"119","author":"Jessup","year":"2009","journal-title":"Circulation"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000006239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:44:44Z","timestamp":1620960284000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201703030-00041"}},"subtitle":["A nested case-control study"],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000006239","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}